Health Canada approves Essure:
This article was originally published in Clinica
Executive Summary
The third-generation Essure birth control system developed by Conceptus has been approved for sale in Canada. The Mountain View, California company said that the system incorporates modifications to facilitate implantation of the device. In addition, hysteroscopic visualisation of the implant and placement markers has been significantly improved. A new DryFlow Introducer, which alleviates distension fluid loss - a major safety concern of hysteroscopists - is packaged with the product. The device is now approved for sale in Canada, the US, Mexico, Central and South America, New Zealand, Australia and Europe.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.